Drug Trial Radar · NCT06430528
A Block-and-Replace Therapy With Osilodrostat and Concomitant Glucocorticoid Replacement
Last checked: Nov 20, 2026Latest source record: Sep 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
12
Planned (sponsor's estimate)
Start
Jul 19, 2024
Primary completion
Oct 2027
Study completion Jan 2028
Sponsor
- Lead sponsor
- University of MichiganAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- RECORDATI GROUP
- First posted
- May 28, 2024
Design
- Study type
- Observational
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The major goal of this study is to determine the incidence of adrenal insufficiency in patients with endogenous Cushing syndrome receiving osilodrostat treatment combined with a replacement of glucocorticoid (block-and-replace approach). The investigators are also evaluating new biomarker steroids to reflect adequate osilodrostat dosing, the durability and safety, and clinical improvement during treatment.
Conditions
- Endogenous Cushing Syndrome
- Adrenal Insufficiency
- Hypercortisolism
Interventions
OsilodrostatDrug
Add methylprednisolone to osilodrostat therapy after first dose and continue during osilodrostat titration.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent of participants who experience an adrenal insufficiency event during Phase 1 (titration phase)Time frame: Through phase 1, approximately 24 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of Michigan
Ann Arbor, Michigan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.